Replimune Group Stock Today
| REPL Stock | USD 7.75 0.82 11.83% |
PerformanceWeakest
| Odds Of DistressAverage
|
Replimune is selling for 7.75 as of the 9th of February 2026. This is a 11.83 percent increase since the beginning of the trading day. The stock's lowest day price was 7.12. Replimune has 52 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. The performance scores are derived for the period starting the 11th of November 2025 and ending today, the 9th of February 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 20th of July 2018 | Category Healthcare | Classification Health Care |
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts. Replimune operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 82.57 M outstanding shares of which 14.4 M shares are at this time shorted by private and institutional investors with about 11.52 trading days to cover. More on Replimune Group
Moving together with Replimune Stock
Moving against Replimune Stock
Replimune Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO, Director | Robert Coffin | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsBy employing borrowed capital, Replimune can potentially magnify investment returns. Examining the debt-to-assets ratio offers investors perspective on Replimune's use of financial leverage and reveals what portion of Replimune's asset base relies on creditor financing.
| ||||||||||||||||||||||||||||||||||||||||||||||
Replimune Group (REPL) is traded on NASDAQ Exchange in USA and employs 479 people. Replimune is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 639.94 M. Replimune Group conducts business under Biotechnology sector and is part of Health Care industry. The entity has 82.57 M outstanding shares of which 14.4 M shares are at this time shorted by private and institutional investors with about 11.52 trading days to cover.
Replimune Group currently holds about 395.08 M in cash with (192.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Replimune Probability Of Bankruptcy
Ownership AllocationThe majority of Replimune Group outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Replimune Group to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Replimune. Please pay attention to any change in the institutional holdings of Replimune Group as this could imply that something significant has changed or is about to change at the company.
Check Replimune Ownership Details
Replimune Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Marshall Wace Asset Management Ltd | 2025-06-30 | 1.9 M | |
| Sofinnova Ventures | 2025-06-30 | 1.8 M | |
| Geode Capital Management, Llc | 2025-06-30 | 1.6 M | |
| Dimensional Fund Advisors, Inc. | 2025-06-30 | 1.2 M | |
| Goldman Sachs Group Inc | 2025-06-30 | 1.1 M | |
| Mpm Oncology Impact Management Lp | 2025-06-30 | 983.8 K | |
| Wellington Management Company Llp | 2025-06-30 | 944.5 K | |
| Morgan Stanley - Brokerage Accounts | 2025-06-30 | 921.7 K | |
| Rosalind Advisors, Inc. | 2025-06-30 | 900 K | |
| Baker Bros Advisors Lp | 2025-06-30 | 11 M | |
| T. Rowe Price Associates, Inc. | 2025-06-30 | 10.8 M |
Replimune Historical Income Statement
Replimune Stock Against Markets
Replimune Corporate Management
| Colin Love | Chief Officer | Profile | |
| Christopher Sarchi | Chief Officer | Profile | |
| Carolyn Trott | Senior Assurance | Profile | |
| Pamela Esposito | Chief Business Officer | Profile | |
| Paul Bullock | Chief Head | Profile | |
| Kari Jeschke | Senior Affairs | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Replimune Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Replimune. Anticipated expansion of Replimune directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Replimune assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Replimune Group is measured differently than its book value, which is the value of Replimune that is recorded on the company's balance sheet. Investors also form their own opinion of Replimune's value that differs from its market value or its book value, called intrinsic value, which is Replimune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Replimune's market value can be influenced by many factors that don't directly affect Replimune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Replimune's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Replimune should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Replimune's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.